Stocks · News reference
Lineage Cell Therapeutics has provided a progress update on its ReSonance (ANP1) cell transplant program for hearing loss, which is being developed under a research collaboration.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Lineage Cell Therapeutics (AMEX:LCTX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For
Filed: 2026-08-06 AccNo: 0001193125-26-338020 Size: 793 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits